Altimmune Secures $75M from Institutional Investor in Direct Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Securities Purchase Agreement: Altimmune has entered into a securities purchase agreement with a new institutional investor for the sale of 17.05 million shares, expected to raise approximately $75 million through a registered direct offering, thereby strengthening the company's financial foundation for future growth.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated to fund preparations for its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis, as well as for working capital and general corporate purposes, ensuring adequate funding during critical R&D phases.
- Transaction Timeline: The offering is expected to close on or about January 29, 2026, indicating Altimmune's proactive approach in the capital markets aimed at securing necessary funding for its clinical trials.
- Positive Stock Reaction: Following the announcement, Altimmune's stock price rose by 3% during after-market trading, reflecting a positive market response to the financing news and potentially boosting investor confidence in the company's future prospects.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.660
Low
12.00
Averages
13.00
High
14.00
Current: 5.660
Low
12.00
Averages
13.00
High
14.00
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
